A trailblazer in psilocybin studies, Dr. Roland Griffiths passed away at age 77 on October 16, 2023, of colon cancer.
More than 24 years ago, Roland Griffiths, PhD, began a groundbreaking research program with a study that investigated the effects of high-doses of psilocybin in healthy volunteers in a controlled setting (1). With the results from this study and the many more studies on psilocybin that followed, he is credited as helping to bring psychedelics back into the field of research (1,2).
Dr. Griffiths began at Johns Hopkins in 1972, after earning his PhD from the University of Minnesota (1). He was a distinguished Professor in the Departments of Psychiatry and Neurosciences at Johns Hopkins University School of Medicine and his research, both in clinical and preclinical laboratories, included the effects of mood-altering drugs, caffeine, and other substances (3).
One of his several noteworthy studies was, “Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance,” a double-blind study on the short- and long-term effects of a high dose of psilocybin, published in 2006 (4). “When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences,” concluded part of the abstract from the study (4). “The ability to occasion such experiences prospectively will allow rigorous scientific investigations of their causes and consequences.”
Dr. Griffiths authored more than 400 journal articles and chapters, and also trained more than 50 postdoctoral research fellows (3). His work received grants from the National Institute of Health (NIH), where he also served as a consultant (1,3).
“Although Dr. Griffiths will not be around to see all the fruits of his labor, his influence of his legacy will reverberate well beyond his passing,” wrote one article covering his life and accomplishments (5). “One of the psychedelic industry’s true shining lights.”
“A hallmark feature of [psychedelic] experiences is that we’re all in this together,” Dr. Griffiths stated earlier this year (1). “It opens people up to this sense that we have a commonality and that we need to take care of each other.”
References
House Budget Bill Amendment Could End Veterans Affairs Medical Cannabis Ban
July 14th 2025The “Big, Beautiful Bill” signed recently into law by President Donald Trump, includes an amendment that may end the medical cannabis ban in the VA which has prevented doctors from recommending the plant to their patients.
Ep 27: Tracking Strains in Diverse Landscapes
July 2nd 2025In this latest installment of Noid Knowledge, we are joined by Daniela Vergara, PhD, Hemp Specialist at the Cornell Cooperative Extension, and Anna Schwabe, PhD, Associate Lecture Professor at the University of Colorado, discussing the evolution of cannabis cultivation and the need for regional climate data. Their recent project, funded by the Agricultural Genomics Foundation, studies 10 cannabis varieties grown by farmers in different regions, specifically plant characteristics, soil type, and harvest metrics. They aim to understand how environmental factors affect cannabis yield and quality, providing actionable insights for farmers and breeders.
Ep 26: Innovations in Drying and Curing to Protect Flower Quality
May 27th 2025In this latest installment of Noid Knowledge, we are joined by Dr. Allison Justice, Founder and CEO of the Hemp Mine, and David Sandelman COO, CTO & Co-Founder of Cannatrol. Here, Allison and David discuss innovations in cannabis drying and curing, focusing on the Cannatrol technology which controls vapor pressure, preserving trichome integrity, and flower quality. Additionally, Allison shares how the Cannabis Research Center and Coalition (CRC) is transition to an open-source model to support cultivators, researchers, and home growers.